NASDAQ:AKYA Akoya Biosciences (AKYA) Stock Price, News & Analysis $2.56 -0.12 (-4.49%) (As of 10/3/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Akoya Biosciences Stock (NASDAQ:AKYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akoya Biosciences alerts:Sign Up Key Stats Today's Range$2.55▼$2.6450-Day Range$1.96▼$2.9452-Week Range$1.88▼$6.31Volume60,612 shsAverage Volume235,714 shsMarket Capitalization$126.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.56Consensus RatingModerate Buy Company OverviewAkoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Read More… Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution Akoya Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks67th Percentile Overall ScoreAKYA MarketRank™: Akoya Biosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 395th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAkoya Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAkoya Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Akoya Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Akoya Biosciences are expected to grow in the coming year, from ($0.98) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akoya Biosciences is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akoya Biosciences is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkoya Biosciences has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akoya Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.98% of the float of Akoya Biosciences has been sold short.Short Interest Ratio / Days to CoverAkoya Biosciences has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.Change versus previous monthShort interest in Akoya Biosciences has recently decreased by 6.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkoya Biosciences does not currently pay a dividend.Dividend GrowthAkoya Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.98% of the float of Akoya Biosciences has been sold short.Short Interest Ratio / Days to CoverAkoya Biosciences has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.Change versus previous monthShort interest in Akoya Biosciences has recently decreased by 6.36%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.44 News SentimentAkoya Biosciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Akoya Biosciences this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akoya Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Akoya Biosciences is held by insiders.Percentage Held by Institutions79.42% of the stock of Akoya Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Akoya Biosciences' insider trading history. Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKYA Stock News HeadlinesAkoya Biosciences Announces Appointment Of Scott Mendel As Chairman Of The Board Of DirectorsOctober 3 at 9:24 PM | markets.businessinsider.comAkoya Biosciences Announces Scott Mendel as Chairman of the Board of DirectorsOctober 3 at 4:00 PM | globenewswire.comElection warning coming true… If you missed it, my emergency election broadcast is now available on replay.October 4, 2024 | Porter & Company (Ad)Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 6.4% in SeptemberOctober 1 at 7:31 AM | americanbankingnews.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives $6.56 Consensus PT from AnalystsSeptember 24, 2024 | americanbankingnews.comCraig-Hallum Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)September 14, 2024 | markets.businessinsider.comMorgan Stanley Downgrades Akoya Biosciences (AKYA)August 7, 2024 | msn.comBTIG Downgrades Akoya Biosciences (AKYA)August 7, 2024 | msn.comSee More Headlines AKYA Stock Analysis - Frequently Asked Questions How have AKYA shares performed this year? Akoya Biosciences' stock was trading at $4.88 at the start of the year. Since then, AKYA shares have decreased by 47.6% and is now trading at $2.5550. View the best growth stocks for 2024 here. How were Akoya Biosciences' earnings last quarter? Akoya Biosciences, Inc. (NASDAQ:AKYA) announced its quarterly earnings results on Monday, August, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.27). The firm earned $23.16 million during the quarter, compared to the consensus estimate of $23.61 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 126.38% and a negative net margin of 64.74%. When did Akoya Biosciences IPO? Akoya Biosciences (AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO. How do I buy shares of Akoya Biosciences? Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/05/2024Today10/04/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AKYA CUSIPN/A CIK1711933 Webwww.akoyabio.com Phone855-896-8401FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$6.56 High Stock Price Target$10.00 Low Stock Price Target$3.00 Potential Upside/Downside+156.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,320,000.00 Net Margins-64.74% Pretax Margin-64.63% Return on Equity-126.38% Return on Assets-32.88% Debt Debt-to-Equity Ratio3.43 Current Ratio2.73 Quick Ratio1.98 Sales & Book Value Annual Sales$93.22 million Price / Sales1.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book2.32Miscellaneous Outstanding Shares49,386,000Free Float45,781,000Market Cap$126.18 million OptionableOptionable Beta1.36 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:AKYA) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.